Revolution Medicines announced it will present clinical data from its RAS(ON) inhibitor trials targeting pancreatic cancer at the ESMO Gastrointestinal Cancers Congress in July 2026. The presentations include Phase 1/2 trial results for zoldonrasib combined with chemotherapy or daraxonrasib, and Phase 3 trial posters for daraxonrasib in first-line and adjuvant settings for metastatic pancreatic adenocarcinoma. These data highlight the company's progress in developing targeted therapies for RAS-driven cancers, potentially advancing treatment options for this difficult-to-treat cancer. The event will be held in Munich, Germany, from July 1-4, 2026.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Alpaca, a brokerage infrastructure startup, secured $435 million in funding to enter prime brokerage services, challenging traditional Wall Street firms. The company’s API supports 94% of US equities and powers tokenized stocks for Kraken. Alpaca’s t...
Raymond James Financial's rating was raised to "Buy" after positive investor event disclosures and a promising preview of its upcoming quarterly results. The company is expected to exceed earnings per share consensus for Q3 FY26, driven by strong per...
Bitcoin and Ethereum experienced combined outflows exceeding $59 million as traders moved funds into stablecoins like USDT and fiat currencies, signaling a cautious stance in the crypto market. This rotation reflects a short-term defensive strategy, ...
Whales have accumulated 70 million XRP over the past week, showing strong confidence despite XRP's price consolidating below resistance levels. The XRP Ledger surpassed 8 million activated accounts, indicating growing network adoption across payments...
